Skip to main content

Advertisement

Table 3 Fellow eye conversion to neovascular AMD in the MARINA/ANCHOR trials, Barbazetto et al. [39]

From: A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration

By end of year A B = 46.4 % + (A × 53.5 %)
Cumulative, incremental, conversion rate of the 53.6 % unilateral, neovascular AMD cases at baseline (%) Bilateral involvement (%)
Baseline 0.0 46.4
Year 1 21.2 57.7
Year 2 38.0 66.8
Year 3 49.8 73.1
Year 4 59.5 78.3
Year 5 67.2 82.4
Year 6 73.4 85.7
Year 7 78.5 88.5
Year 8 82.6 90.6
Year 9 85.9 92.4
Year 10 88.6 93.9
Year 11 90.7 95.0
Year 12 92.5 96.0
Final 92.5 96.0
  1. Baseline, year 1 and year 2 prevalences are based upon primary data [39], while years 3–12 are based upon the average incidence of conversion to neovascular during years 1 and 2, using a last observation carried forward (LOCF) methodology with Markov modeling
  2. AMD age-related macular degeneration